» Articles » PMID: 27472708

Association Between Anti-HBc Positivity and Hepatocellular Carcinoma in HBsAg-negative Subjects with Chronic Liver Disease: A Meta-analysis

Overview
Specialty General Medicine
Date 2016 Jul 30
PMID 27472708
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

A meta-analysis was performed to ascertain to what extent hepatitis B surface antigen (HBsAg)-negative/anti-hepatitis B core (anti-HBc)-positive subjects with chronic liver disease are at a higher risk of developing hepatocellular carcinoma (HCC) than the anti-HBc-negative.All studies included had to fulfill the following characteristics and inclusion criteria: they investigated the relationship between HBsAg-negative/anti-HBc-positive serology and the occurrence of HCC, whether a case-control or cohort study, they provided relative risk (RR) or odds ratios (ORs) and 95% confidence intervals (CIs), were available as a full text written in English, and were published and indexed up to April 2015.Twenty-six original studies met the inclusion criteria, allowing a meta-analysis on 44,553 patients. The risk of HCC among the 9986 anti-HBc-positive subjects was 67% higher than in the 34,567 anti-HBc-negative (95% CI = 1.44-1.95, P < 0.0001). The results were similar when groups of patients with a different stage of liver disease (patients with chronic liver disease, patients with cirrhosis), with different ethnicity (Asian and non-Asian) and etiology (HCV and non-HCV) were considered. The risk of HCC was significantly higher in the 651 anti-HBs/anti-HBc-positive patients (RR = 1.36; 95% CI = 1.17-1.58, P = 0.03) and in the 595 anti-HBs-negative/anti-HBc-positive subjects (RR = 2.15; 95% CI = 1.58-2.92, P < 0.0001) than in the 1242 anti-HBs/anti-HBc negative. However, the RR from 8 studies indicated that the risk of HCC was 35% lower among the anti-HBs/anti-HBc-positive subjects compared to the anti-HBs-negative/anti-HBc-positive (RR = 0.65; 95% CI = 0.52-0.8, P < 0.0001).This meta-analysis shows that in HBsAg-negative subjects with chronic liver disease, anti-HBc positivity is strongly associated with the presence of HCC, an association observed in all subgroups according to the stage of the disease, etiology, and ethnicity.

Citing Articles

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.

Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D Ann Med. 2025; 57(1):2455539.

PMID: 39834076 PMC: 11753015. DOI: 10.1080/07853890.2025.2455539.


Reactivation of hepatitis B virus infection - an important aspect of multifaceted problem.

Morozov S, Batskikh S World J Gastroenterol. 2024; 30(26):3193-3197.

PMID: 39086636 PMC: 11287409. DOI: 10.3748/wjg.v30.i26.3193.


Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen.

Yano Y, Sato I, Imanishi T, Yoshida R, Matsuura T, Ueda Y Diagnostics (Basel). 2024; 14(7).

PMID: 38611641 PMC: 11011781. DOI: 10.3390/diagnostics14070728.


The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample.

Freeland C, Sreepathi V, Hass R, Fenkel J, Torgersen J, Rothstein K J Virus Erad. 2024; 9(4):100358.

PMID: 38174110 PMC: 10761777. DOI: 10.1016/j.jve.2023.100358.


HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program.

Sono S, Sae-Chan J, Kaewdech A, Chamroonkul N, Sripongpun P PLoS One. 2022; 17(6):e0270458.

PMID: 35749545 PMC: 9231792. DOI: 10.1371/journal.pone.0270458.


References
1.
Gotsman I, Alper R, Klein A, Rabbani E, Engelhardt D, Ilan Y . Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Cancer. 2002; 94(2):406-14. DOI: 10.1002/cncr.10237. View

2.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

3.
Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H . Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2003; 48(9):1786-92. DOI: 10.1023/a:1025459431613. View

4.
Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M . Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995; 21(3):650-5. View

5.
Shiratori Y, Shiina S, Zhang P, Ohno E, Okudaira T, Payawal D . Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan?. Cancer. 1997; 80(11):2060-7. View